Active Surveillance vs. Treatment for Low-Risk Prostate Cancer: How Doctors Decide

Research-informed explainer — last updated April 12, 2026

For most men with low-risk prostate cancer, the safest choice may be to watch and wait rather than rush to surgery or radiation — and nearly two decades of trial data back this up. Knowing when that calculus changes requires understanding your specific tumor grade, PSA trajectory, and overall health, not just a cancer diagnosis.

This article draws on research from five urologic oncologists who helped define the evidence for active surveillance. William Aronson, MD, of UCLA and Olive View-UCLA Medical Center, co-led the landmark PIVOT trial that followed 731 men for up to 20 years and found radical prostatectomy did not significantly reduce all-cause or prostate cancer mortality compared with observation for localized disease. Peter Carroll, M.D., Chair of Urology at UCSF Helen Diller Medical Center, developed the UCSF CAPRA risk score and published foundational research on overdiagnosis and treatment trends showing surveillance use doubled after 2010. Christopher Kane, M.D., Professor of Urology at UC San Diego, co-authored the NCCN prostate cancer guidelines that define national eligibility criteria for surveillance. James McKiernan, MD, Director of Urologic Oncology at NewYork-Presbyterian/Columbia, published multi-institutional prospective deferred intervention data. Jeffrey Cadeddu, MD, Director of Minimally Invasive Therapy at UT Southwestern, co-authored the joint AUA/ASTRO/SUO guideline for localized prostate cancer.

What active surveillance actually means

Active surveillance (AS) is not the same as watchful waiting. In watchful waiting, a patient forgoes treatment unless symptoms develop — often chosen by older men with short life expectancy. Active surveillance is an intensive monitoring program designed for men with favorable-risk cancer who are appropriate candidates for curative treatment but whose disease is unlikely to progress rapidly.

Standard AS protocols typically include PSA testing every 3 to 6 months, digital rectal exam annually, repeat prostate biopsy at 1 to 2 years after diagnosis and periodically thereafter, and increasingly, multiparametric MRI to detect reclassification before biopsy.

The goal is to detect progression early enough that curative treatment remains possible — while avoiding years of treatment side effects in men whose cancer would never have caused harm.

The PIVOT trial: the defining evidence

The Prostate Intervention versus Observation Trial (PIVOT) enrolled 731 men with localized prostate cancer and randomized them to radical prostatectomy versus observation. After 12 years of follow-up, the trial found that surgery did not significantly reduce all-cause mortality (hazard ratio 0.88, p=0.09) or prostate cancer-specific mortality compared with observation. Absolute differences in prostate cancer mortality were less than 3 percentage points.

The 2017 PIVOT follow-up paper — extending follow-up to nearly 20 years — confirmed this finding. Surgery was not associated with significantly lower all-cause or prostate cancer mortality than observation across the full cohort. Surgery did reduce treatment for disease progression, but much of that progression was asymptomatic, local, or biochemical — not the kind of progression that kills men.

The key nuance: PIVOT showed subgroup effects. Men with intermediate- or high-risk disease and men younger than 65 appeared to derive greater relative benefit from surgery. The study reinforced that for low-risk disease, observation is a genuinely safe approach.

How risk is stratified before a decision is made

Not every man with prostate cancer is a surveillance candidate. Guidelines from the NCCN (Version 2.2019, co-authored by Dr. Kane) and the AUA/ASTRO/SUO joint guideline (co-authored by Dr. Cadeddu) define eligibility based on a combination of clinical, pathological, and molecular factors.

Typical low-risk criteria that favor surveillance:

• PSA below 10 ng/mL
• Clinical stage T1c or T2a (organ-confined, not palpable or minimal)
• Gleason score 6 (Grade Group 1) on biopsy
• Fewer than 3 positive biopsy cores, with less than 50% of any single core involved

The UCSF CAPRA score, developed by Dr. Carroll, combines PSA, Gleason grade, clinical stage, positive biopsy percentage, and patient age into a 0–10 point scale. Scores 0–2 indicate low risk. External validation confirmed the CAPRA score predicts biochemical recurrence after surgery across multiple independent cohorts.

Factors that push toward treatment:

• Gleason score 7 or higher (Grade Group 2+)
• More than 3 positive cores
• PSA velocity doubling in under 3 years
• Upgrading on repeat biopsy or MRI-visible lesion growth
• Younger patient age with long life expectancy
• Patient anxiety with surveillance protocol

Comparison: active surveillance vs. immediate treatment

When to switch from surveillance to treatment

The signal to intervene is not a fixed PSA threshold. Instead, clinicians look for reclassification — evidence that the tumor is behaving more aggressively than initially assessed. This includes:

• Upgrade in Gleason grade on repeat biopsy (6 to 7 or higher)
• Significant increase in percent core involvement
• MRI showing new or growing lesion (PI-RADS 4 or 5)
• PSA doubling time under 2-3 years
• Patient decision to end surveillance

Research from James McKiernan's group showed that in multi-institutional prospective cohorts, roughly 30% of men enrolled in active surveillance protocols undergo deferred intervention within 5 years — most due to biopsy reclassification rather than symptomatic progression.

The overtreatment problem

Peter Carroll's 2014 paper in European Urology documented the scale of overtreatment driven by widespread PSA screening before evidence-based guidelines existed. Thousands of men received prostatectomies or radiation for Gleason 6 tumors that would never have caused clinical harm during their lifetime. The subsequent shift to surveillance-first for low-risk disease was driven by accumulating data showing that the side effects of treatment — erectile dysfunction, urinary incontinence, bowel symptoms — caused real measurable harm without offsetting mortality benefit.

Since 2010, surveillance use has grown substantially. A registry study using CaPSURE data showed that primary surveillance rates among low-risk patients increased from roughly 10% before 2010 to over 40% in recent years as guidelines evolved.

Questions to ask your doctor

• What is my Gleason grade group, PSA level, and number of positive cores — and do these put me in a low-, intermediate-, or high-risk category?
• Would I benefit from a multiparametric MRI before deciding on surveillance?
• What does your practice's surveillance protocol look like — how often will I need repeat biopsies?
• What specific findings would prompt you to recommend switching to treatment?
• Am I a candidate for molecular testing (like Decipher or Oncotype DX Genomic Prostate Score) to refine my risk estimate?
• What is your practice's experience with men who have remained on surveillance for 5 or 10 years?

The bottom line

For men with low-risk, Gleason 6 prostate cancer, nearly 20 years of randomized data — including the PIVOT trial — show that active surveillance carries the same cancer-specific mortality as immediate surgery or radiation. The decision between surveillance and treatment is driven by grade, PSA behavior, patient age, and personal tolerance for ongoing monitoring. Men with intermediate- or high-risk features, younger patients with long life expectancy, and those who find surveillance psychologically intolerable are more appropriate treatment candidates. The goal of surveillance is not to avoid treatment permanently — it is to treat only the men whose cancer truly requires it.